Aquestive Therapeutics, Inc. ( (AQST) ) has released its Q2 earnings. Here is a breakdown of the information Aquestive Therapeutics, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on developing innovative, orally administered products to improve patient care, particularly in the treatment of severe allergic reactions and other medical conditions. The company is known for its proprietary delivery technologies and collaborations with other pharmaceutical firms.
Aquestive Therapeutics recently reported its financial results for the second quarter of 2025, highlighting significant progress in its product pipeline. The FDA has accepted the New Drug Application for Anaphylm™, a sublingual film for epinephrine delivery, with a potential U.S. launch planned for early 2026, pending approval. The company is also preparing for Anaphylm’s global expansion, targeting markets in Canada and the EU.
Key financial metrics from the second quarter indicate a total revenue of $10.0 million, reflecting a 3% year-over-year increase when excluding one-time deferred revenue recognition from the previous year. Manufacturing and supply revenue rose to $9.6 million, driven by increased sales of Ondif. However, the company reported a net loss of $13.5 million, primarily due to increased selling, general, and administrative expenses. Aquestive is also advancing its AQST-108 topical gel for alopecia areata, with plans to submit an Investigational New Drug Application by the end of 2025.
Despite the financial losses, Aquestive remains optimistic about its future prospects. The company is focused on executing its strategic plans, including the potential launch of Anaphylm and further development of its product candidates. Management is confident in its ability to address unmet medical needs and expand its market presence globally, positioning itself for long-term growth.